

Supplementary Table 2: Characteristics of patients treated with Rituximab.

Patient	Concomitant therapy	Former therapy	DAS28	RF	ACPA	HLA
1 RA	MTX, Prednisolone	Sulfasalazine, Azathioprine, Chloroquine, Tocilizumab, TNF- α blocker	2.5	+	+	1
2 RA	Hydroxychloroquine, Prednisolone, Sulfasalazine	MTX, Abatacept, TNF- α blocker	4.2	+	+	1
3 RA	MTX + Prednisolone	Leflunomid, TNF- α blocker	4.5	+	+	1
4 RA	Hydroxychloroquine	MTX, Sulfasalazine, Azathioprine, Leflunomide, TNF- α blocker	4.0	+	+	1
5 RA		MTX, Azathioprine, Leflunomide,	2.8	-	-	2
1 GPA	Prednisolone	Cyclophosphamide	-	-	-	-

Therapies, DAS28 score, seropositivity of rheumatoid factor (RF) and antibodies against cyclic citrullinated peptides (ACPA), and number of identified human leukocyte antigen (HLA) haplotypes which are suitable for influenza-specific T cell analysis are indicated.